Sionna Therapeutics (NASDAQ:SION) Director Sells $2,128,201.14 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 47,814 shares of the firm’s stock in a transaction that occurred on Tuesday, April 14th. The shares were sold at an average price of $44.51, for a total transaction of $2,128,201.14. Following the completion of the transaction, the director owned 3,482,888 shares in the company, valued at $155,023,344.88. The trade was a 1.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sionna Therapeutics Stock Performance

NASDAQ SION opened at $43.54 on Friday. Sionna Therapeutics, Inc. has a one year low of $10.07 and a one year high of $46.46. The company’s 50 day moving average price is $37.74 and its 200 day moving average price is $38.39. The firm has a market capitalization of $1.96 billion, a price-to-earnings ratio of -22.33 and a beta of 3.01.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.15.

Key Stories Impacting Sionna Therapeutics

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: The company reported an EPS beat on March 2 (reported -$0.46 vs. consensus -$0.61), a fundamental datapoint that supports investor sentiment and helps explain why the stock has traded above its 50/200‑day averages.
• Positive Sentiment: Despite selling, the reporting director (Orbimed / Peter A. Thompson) still holds a very large stake (roughly 3.0–3.5M shares), which tempers the interpretation that insiders are deserting the company.
• Neutral Sentiment: Many of the reported sales were executed under pre‑arranged Rule 10b5‑1 plans, which reduces the likelihood the trades reflect new negative private information.
• Neutral Sentiment: Analyst coverage is skewed positive: multiple buy/strong‑buy ratings and an average target (~$50.6) provide a supportive backdrop for sentiment.
• Negative Sentiment: Large, consecutive insider sell filings on April 14–16 total roughly 510K shares (~$22–23M at reported prices). That scale of director selling can create short‑term downward pressure and trigger investor concern despite 10b5‑1 protections. InsiderTrades Alert SEC Filing

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Citizens Jmp assumed coverage on shares of Sionna Therapeutics in a research note on Tuesday, February 24th. They set a “market outperform” rating and a $63.00 price objective on the stock. Guggenheim lifted their price objective on shares of Sionna Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Citigroup assumed coverage on shares of Sionna Therapeutics in a research note on Tuesday, February 24th. They set an “outperform” rating on the stock. UBS Group reiterated a “buy” rating on shares of Sionna Therapeutics in a research note on Monday, March 2nd. Finally, Raymond James Financial reiterated a “strong-buy” rating and set a $53.00 price objective on shares of Sionna Therapeutics in a research note on Monday, January 5th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.57.

Institutional Trading of Sionna Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. GF Fund Management CO. LTD. bought a new stake in shares of Sionna Therapeutics in the fourth quarter worth $36,000. Russell Investments Group Ltd. bought a new stake in shares of Sionna Therapeutics in the third quarter worth $30,000. Balyasny Asset Management L.P. bought a new stake in shares of Sionna Therapeutics in the fourth quarter worth $58,000. BNP Paribas Financial Markets bought a new stake in shares of Sionna Therapeutics in the second quarter worth $31,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Sionna Therapeutics in the fourth quarter worth $89,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.